Latest news
How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche - webull.comwebull.com · Thu, 06 Aug 2026 22:01:13 GMTNurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272 - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 07:37:44 GMTNurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 11:00:00 GMTNurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLL - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 06:33:26 GMTNurix enrolls first patient in Phase 3 trial te... - PluangPluang · Tue, 04 Aug 2026 05:39:29 GMTNurix enrolls first patient in phase 3 trial for CLL drug - Investing.comInvesting.com · Tue, 04 Aug 2026 05:12:46 GMTNurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLL - Quiver QuantitativeQuiver Quantitative · Tue, 04 Aug 2026 05:10:00 GMTNurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - Stock TitanStock Titan · Tue, 04 Aug 2026 05:03:02 GMT